---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035040"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:37:36.117262+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics reports Q3 net loss $12.2M; cash $18.5M; Phase 2 stenoparib patients exceed one year on treatment

## Summary
- Net loss $12.2M vs $5.6M YoY; includes $9.7M non-cash intangible impairment charge.
- Cash and equivalents $18.5M at Sept 30, 2024, up from $0.2M at Dec 31, 2023; runway into 2026.
- Phase 2 stenoparib trial: two ovarian cancer patients exceeded one year on treatment.
- Appointed Alexander Epshinsky as CFO; Jeremy Graff as President/Chief Development Officer; Jose Iglesias as Consultant CMO.
- Regained NASDAQ compliance; European patent granted for stenoparib DRP companion diagnostic.

## SEC filing metadata
- accession: 0001437749-24-035040
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/0001437749-24-035040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/allr20241010c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035040
- JSON: https://secwatch.observer/filing/0001437749-24-035040.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.